Europe Biopharmaceutical Contract Manufacturing Market

Europe Biopharmaceutical Contract Manufacturing Market Size  (2024 to 2029)

As per the research report, the size of the Europe Biopharmaceutical Contract Manufacturing market is valued at USD 1.79 billion in 2024. It is expected to rise at a CAGR of 9.3% capping the market to USD 2.80 billion by 2029 during the forecast period 2024 to 2029.

Biopharmaceuticals are biological products that are made and developed to help with illness prevention and treatment. Recent advances in bio manufacturing and biotechnology have sparked the development of novel technologies capable of tackling the challenges associated with the production of biopharmaceuticals. As a result, the biopharmaceuticals contract manufacturing market is expanding.

The biopharmaceutical contract manufacturing market is primarily driven by the faster pace of production with contract manufacturing organizations, less cost than own manufacturing facilities, entry-level pharmaceutical production enterprises searching for investors. Furthermore, faster approvals for patent sharing, intellectual property copyright rules, higher demand for drugs by people, lower production capacity, and other factors are expected to boost the growth rate of the biopharmaceutical contract manufacturing industry. Instead of manufacturing every drug independently, they opt for contractual obligations with small companies to produce medicines through MOUs or investments.

Pharmaceutical companies see this as an opportunity to decrease their manufacturing costs by outsourcing these functions. As a result, production costs can be shifted to the research and development division, allowing for more efficient discoveries. Moreover, the rise of the biopharmaceutical contract manufacturing business presents an opportunity for CMOs in the form of mergers, acquisitions, and joint ventures with large corporations. These initiatives help CMOs see the possibilities for making their companies more financially secure and technologically adept.

The biopharmaceutical contract manufacturing market is constrained by several factors, including small enterprises' lack of technological knowledge in biopharmaceutical manufacturing, abuse of patent sharing details, and easy reverse engineering of the drug composition formula. These factors drive pharma behemoths to build their production facilities, putting the efficacy of contract manufacturing firms at risk. In addition, the lack of intellectual property restrictions in many countries and unrestricted patent rights in others also hinder contract manufacturing companies' market growth.

This research report on the Europe Biopharmaceutical Contract Manufacturing Market has been segmented and sub-segmented into the following categories:

By Product Type:

• Insulin
• Monoclonal Antibodies
• Growth Factors
• Interferons
• Recombinant Proteins
• Vaccines
• Others

By Therapeutic Area:

• Infectious Disease
• Cardiovascular Disease
• Oncology
• Metabolic Disease
• Respiratory Disorder
• Autoimmune Disease
• Neurology
• Ophthalmology
• Others

By Application:

• Commercial
• Clinical

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic

• Rest of Europe

Geographically, the Europe held the second-largest share of the biopharmaceutical contract manufacturing market. The biopharmaceutical business in Europe is regulated by the European Medicines Agency and is subject to rigorous patent rights. The location has cutting-edge technologies for producing medications with maximum efficiency. Recommended new pharmaceuticals that enter the market after getting product clearance also significantly impact the market. The countries like Germany, France, the United Kingdom, Italy, Spain, and the rest of Europe, are expected to contribute to the European biopharmaceutical contract manufacturing market.

In recent years, there has been a slew of new entrants into the field of CMOS. This has allowed the major pharmaceutical companies to lessen the burden of developing and manufacturing each new medicine on their own in the European biopharmaceutical contract manufacturing market.

Moreover, the major players in the region are implementing various strategies to gain a competitive advantage over the marketplace. The techniques include mergers, partnerships, and acquisitions. For instance, Sanofi has contracted Boehringer Ingelheim to manufacture its biologics program. In addition, many businesses are turning to CMOs to expedite the development process and reduce production expenses.

Rentschler, which is trying to expand globally, added a new facility to its Laupheim, Germany, plant two years ago to increase capacity, citing the increased need for biologics.

KEY MARKET PLAYERS

Key players operating in the Europe Biopharmaceutical contract manufacturing market profiled in this report are Lonza Group AG, Baxter Biopharma Solutions, Samsung Biologics Co., Ltd., Fujifilm Diosynth Biotechnologies, Boehringer Ingelheim GmbH, Patheon N.V., Rentschler Biotechnologie GmbH, Biomeva GmbH, Probiogen AG, Cytovance Biologics, Inc., KBI Biopharma, Inc., WuXi Biologics, Abzena Plc, Vetter Pharma International GmbH, Sandoz International GmbH, Catalent, Inc., AbbVie Contract Manufacturing (An AbbVie Company), Ajinomoto Althea Inc.